Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. (SHE:300937)
China · Delayed Price · Currency is CNY 34.12
+0.14 (0.41%)
At close: Feb 27, 2026
SHE:300937 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 4,355 | 4,348 | 4,407 | 3,946 | 3,384 | 2,774 |
Other Revenue | 32.87 | 32.87 | 23.54 | 23.65 | 16.23 | 15.84 |
| 4,387 | 4,381 | 4,430 | 3,969 | 3,401 | 2,790 | |
Revenue Growth (YoY) | -1.48% | -1.12% | 11.62% | 16.72% | 21.88% | 21.87% |
Cost of Revenue | 3,928 | 4,001 | 4,073 | 3,663 | 3,219 | 2,596 |
Gross Profit | 459.22 | 379.82 | 357.85 | 306.05 | 181.48 | 194.4 |
Selling, General & Admin | 402.48 | 321.89 | 247.44 | 218.86 | 164.5 | 125.01 |
Research & Development | 11.08 | 15.47 | 19.32 | 17.71 | 11.38 | - |
Other Operating Expenses | 7.79 | 7.21 | 7.4 | 6.47 | 5.11 | 5.26 |
Operating Expenses | 430.14 | 350.66 | 283.89 | 247.86 | 181.44 | 131.88 |
Operating Income | 29.08 | 29.16 | 73.97 | 58.19 | 0.04 | 62.51 |
Interest Expense | -8.56 | -9.71 | -6.58 | -6.42 | -1.82 | -1.82 |
Interest & Investment Income | 4.23 | 3.87 | 3.81 | 2.38 | 9.65 | 2.1 |
Currency Exchange Gain (Loss) | 0 | 0 | -0 | -0 | - | - |
Other Non Operating Income (Expenses) | -6.49 | -4.66 | -6.17 | -10.31 | -3.94 | -3.59 |
EBT Excluding Unusual Items | 18.27 | 18.66 | 65.02 | 43.83 | 3.93 | 59.2 |
Impairment of Goodwill | - | - | - | -1.62 | - | - |
Gain (Loss) on Sale of Investments | -1.37 | -1.84 | - | -4.29 | - | - |
Gain (Loss) on Sale of Assets | 0.05 | -0.61 | -0.05 | -0.08 | -0.11 | -0.06 |
Asset Writedown | -7.13 | 0.4 | -0.01 | -0.11 | -0 | -0.03 |
Other Unusual Items | 0.56 | 0.56 | 4.92 | 7.16 | 4.3 | 2.72 |
Pretax Income | 10.38 | 17.18 | 69.88 | 44.89 | 8.12 | 61.83 |
Income Tax Expense | 13.66 | 1.78 | 13.11 | 8.75 | 1.4 | 9.41 |
Earnings From Continuing Operations | -3.28 | 15.4 | 56.77 | 36.14 | 6.73 | 52.42 |
Minority Interest in Earnings | -2.65 | 0.96 | 2.76 | 5.88 | -0.33 | 1.6 |
Net Income | -5.93 | 16.36 | 59.53 | 42.02 | 6.4 | 54.02 |
Net Income to Common | -5.93 | 16.36 | 59.53 | 42.02 | 6.4 | 54.02 |
Net Income Growth | - | -72.52% | 41.69% | 556.48% | -88.15% | -16.46% |
Shares Outstanding (Basic) | 96 | 96 | 96 | 95 | 91 | 72 |
Shares Outstanding (Diluted) | 96 | 96 | 96 | 95 | 91 | 72 |
Shares Change (YoY) | 3.08% | 0.21% | 0.56% | 4.44% | 26.94% | 0.24% |
EPS (Basic) | -0.06 | 0.17 | 0.62 | 0.44 | 0.07 | 0.75 |
EPS (Diluted) | -0.06 | 0.17 | 0.62 | 0.44 | 0.07 | 0.75 |
EPS Growth | - | -72.58% | 40.91% | 528.57% | -90.67% | -16.67% |
Free Cash Flow | -45.91 | 95.48 | -150.8 | 134.35 | -185.81 | 34.1 |
Free Cash Flow Per Share | -0.48 | 0.99 | -1.57 | 1.41 | -2.03 | 0.47 |
Dividend Per Share | 0.100 | 0.100 | 0.220 | 0.200 | - | 0.200 |
Dividend Growth | -54.55% | -54.55% | 10.00% | - | - | - |
Gross Margin | 10.47% | 8.67% | 8.08% | 7.71% | 5.34% | 6.97% |
Operating Margin | 0.66% | 0.67% | 1.67% | 1.47% | 0.00% | 2.24% |
Profit Margin | -0.14% | 0.37% | 1.34% | 1.06% | 0.19% | 1.94% |
Free Cash Flow Margin | -1.05% | 2.18% | -3.40% | 3.38% | -5.46% | 1.22% |
EBITDA | 48.4 | 48.37 | 93.03 | 77.46 | 13.37 | 72.55 |
EBITDA Margin | 1.10% | 1.10% | 2.10% | 1.95% | 0.39% | 2.60% |
D&A For EBITDA | 19.32 | 19.21 | 19.06 | 19.27 | 13.33 | 10.04 |
EBIT | 29.08 | 29.16 | 73.97 | 58.19 | 0.04 | 62.51 |
EBIT Margin | 0.66% | 0.67% | 1.67% | 1.47% | 0.00% | 2.24% |
Effective Tax Rate | 131.58% | 10.34% | 18.76% | 19.50% | 17.17% | 15.22% |
Revenue as Reported | 6.66 | - | - | 3,969 | 3,401 | 2,790 |
Advertising Expenses | - | 76.51 | 36.27 | 28.48 | 19.98 | 9.61 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.